Trials / Recruiting
RecruitingNCT05100069
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
General Use-results Survey of Alunbrig Tablets "Non-small Cell Lung Cancer"
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brigatinib | Brigatinib Tablets |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2030-09-30
- Completion
- 2030-09-30
- First posted
- 2021-10-29
- Last updated
- 2026-03-17
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05100069. Inclusion in this directory is not an endorsement.